Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 26Pancreatic Neoplasms 12Stomach Neoplasms 11Colonic Neoplasms 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Adenocarcinoma Of Esophagus 7Burkitt Lymphoma 6Neoplasms 5Cholangiocarcinoma 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lung Neoplasms 2Leukemia, Biphenotypic, Acute 2Leukemia 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Unresectable Colorectal Cancer 1

Interventions

Leucovorin 1Gemcitabine 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urachal cancer × Leucovorin × Clear all
NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled
Genitourinary

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡